Ixabepilone Journal Article
| Authors: | Conlin, A.; Fornier, M.; Hudis, C.; Kar, S.; Kirkpatrick, P. |
| Article Title: | Ixabepilone |
| Abstract: | Ixabepilone (Ixempra; Bristol-Myers Squibb), a cytotoxic microtubule inhibitor, was approved by the US FDA for the treatment of metastatic breast cancer in October 2007. It is the first member of the epothilone family of anticancer agents to be approved. |
| Keywords: | unclassified drug; clinical trial; fatigue; neutropenia; drug efficacy; drug safety; monotherapy; drug approval; liver dysfunction; united states; drug targeting; capecitabine; paclitaxel; treatment indication; sensory neuropathy; breast cancer; beta tubulin; myalgia; epidermal growth factor receptor 2; antineoplastic activity; drug structure; food and drug administration; docetaxel; cancer inhibition; drug fatality; tumor recurrence; malignant neoplastic disease; vinca alkaloid; taxane derivative; anthracycline derivative; structure analysis; mycobacterium; drug protein binding; ixabepilone; epothilone a; epothilone b; epothilone derivative; ixempra; drug classification |
| Journal Title: | Nature Reviews Drug Discovery |
| Volume: | 6 |
| Issue: | 12 |
| ISSN: | 1474-1776 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2007-12-01 |
| Start Page: | 953 |
| End Page: | 954 |
| Language: | English |
| DOI: | 10.1038/nrd2469 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 20" - "Export Date: 17 November 2011" - "CODEN: NRDDA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work